Clinical trials located in

Bayonne

Bayonne city is located in France. Currently, 14 clinical trials are being conducted in this city.

Bayonne, nestled at the confluence of the Nive and Adour rivers in southwestern France, is renowned for its rich history and vibrant culture. This city, a key part of the French Basque Country, boasts a unique architectural heritage, including the impressive Gothic-style Sainte-Marie Cathedral and the Château-Vieux. Bayonne is also famous for its annual Fêtes de Bayonne, one of France’s largest festivals, and its culinary contributions, notably the Bayonne ham, a delicacy protected by AOC status since 1998. The city’s art and history museum further encapsulates its diverse cultural landscape, making Bayonne a mosaic of historical and contemporary influences.

  • CT-EU-00116791

    Study of Subcutaneous Combination Treatment for Metastatic Melanoma

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Exploring a new treatment combination for rheumatoid arthritis: baricitinib plus anti-TNF

    This clinical trial is focused on finding a more effective treatment for people with Rheumatoid Arthritis (RA) who haven’t responded well to previous therapies. The study is comparing two different approaches: one group will receive a combination of baricitinib treatment and an anti-TNF therapy (adalimumab), while the other group will receive baricitinib along with a placebo. The main goal is to see which group shows a greater improvement in their RA symptoms, specifically looking for a 50% improvement in symptoms, known as an ACR 50 response, after 24 weeks from the start of the treatment.

    Baricitinib is a medication that targets certain pathways in the body’s immune system to reduce inflammation and pain in RA. Anti-TNF therapy, like adalimumab, works by blocking the action of a protein in the body that causes inflammation. By combining these two treatments, researchers hope to see a more significant improvement in RA symptoms than with baricitinib alone.

    The trial is important because it aims to provide a new option for patients with RA who have not found relief with current treatments. It’s designed to test the safety and effectiveness of using these two different types of medications together.

    France
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    BelgiumFranceGermanySpain
  • Research on plitidepsin effectiveness in treating COVID-19

    This research study aims to investigate the benefits and safety of a drug called plitidepsin for COVID-19 patients who have a weakened immune system and require hospital care. The study will administer the drug to some patients, while others will receive standard care, allowing researchers to assess whether plitidepsin can reduce death rates in this specific population. Throughout the study, close monitoring will be conducted to observe any changes, including side effects, serious incidents, or the necessity to discontinue the treatment.

    BelgiumFranceGreeceHungaryItalyPolandPortugalSpain
  • Testing ADT with or without darolutamide in prostate cancer patients

    This study is about testing how well two different kinds of prostate cancer treatment work. One treatment is called ADT (Androgen deprivation therapy) and the other is called darolutamide. In total, around 300 men who have just been diagnosed with prostate cancer will take part. The people in the study will be split into two groups. Half of the people will have the ADT treatment with placebo, while the other half will have both the ADT and darolutamide treatment. This will help the researchers understand whether adding darolutamide makes the ADT treatment work better. To check how well the treatment is working, the researchers will be using different methods.

    BelgiumFranceSpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Breast cancer treatment study: Dato-DXd and durvalumab

    This clinical trial is a comprehensive study aimed at evaluating the effectiveness and safety of advanced treatments for breast cancer, specifically targeting triple-negative and hormone receptor-low/HER2-negative types. The study involves two groups of participants. One group will receive a combination of Dato-DXd and durvalumab as a neoadjuvant (pre-surgery) treatment, followed by durvalumab as an adjuvant (post-surgery) therapy, with or without additional chemotherapy. The other group will be treated with pembrolizumab plus chemotherapy as both neoadjuvant and adjuvant therapies. The goal is to see which method is better at treating the cancer. Additional objectives include evaluating overall survival, distant disease-free survival, and participant-reported outcomes related to symptoms, physical function, fatigue, and quality of life.

    AustriaBelgiumBulgariaFranceGermanyHungaryItalySpainUnited Kingdom
  • Evaluation of the effectiveness of combined therapy in the treatment of bladder cancer with muscle invasion

    This clinical study, known as the VOLGA trial, is for bladder cancer patients who cannot or refuse to take Cisplatin. Two new therapy combinations are being tested. The first combines Durvalumab, Tremelimumab, and Enfortumab Vedotin. The second partners Durvalumab with Enfortumab Vedotin only. Patients receive these drugs both before and after having bladder surgery. This study wants to involve about 830 patients and will assign them blindly to the therapy combinations. Patients will receive the blend for three cycles, with more Durvalumab treatments after surgery. We want to track if the cancer is eradicated after surgery, when the cancer appears again, the survival rate, unwanted effects, and the patients’ well-being. Taking part in this study might require commitment for approximately 3-5 years, with follow-ups to monitor the patient’s progress.

    AustriaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in France:

.